Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Kyverna Therapeutics Inc (KYTX)

Kyverna Therapeutics Inc (KYTX)
2.94 x 5 3.11 x 30
Post-market by (Cboe BZX)
2.97 -0.06 (-1.98%) 02/18/25 [NASDAQ]
2.94 x 5 3.11 x 30
Post-market 2.93 -0.04 (-1.35%) 16:13 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.94
Day High
3.14
Open 3.10
Previous Close 3.03 3.03
Volume 337,000 337,000
Avg Vol 481,100 481,100
Stochastic %K 35.69% 35.69%
Weighted Alpha -89.08 -89.08
5-Day Change -0.04 (-1.33%) -0.04 (-1.33%)
52-Week Range 2.64 - 30.60 2.64 - 30.60
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,811
  • Shares Outstanding, K 43,172
  • Annual Sales, $ 0 K
  • Annual Income, $ -60,370 K
  • EBIT $ -123 M
  • EBITDA $ -121 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.43

Options Overview Details

View History
  • Implied Volatility 281.76% ( +15.14%)
  • Historical Volatility 78.22%
  • IV Percentile 78%
  • IV Rank 32.61%
  • IV High 853.30% on 01/17/25
  • IV Low 5.14% on 03/26/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 24
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 1,290
  • Open Int (30-Day) 1,244

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.84
  • Number of Estimates 4
  • High Estimate -0.70
  • Low Estimate -0.90
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.64 +12.29%
on 02/12/25
Period Open: 3.33
4.06 -26.83%
on 01/27/25
-0.36 (-10.81%)
since 01/17/25
3-Month
2.64 +12.29%
on 02/12/25
Period Open: 4.41
7.20 -58.75%
on 12/02/24
-1.44 (-32.58%)
since 11/18/24
52-Week
2.64 +12.29%
on 02/12/25
Period Open: 29.50
30.60 -90.29%
on 03/14/24
-26.53 (-89.93%)
since 02/16/24

Most Recent Stories

More News
Shareholders That Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky about Pending Class Action - KYTX

New York, New York--(Newsfile Corp. - January 2, 2025) - Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class...

KYTX : 2.97 (-1.98%)
S&P Futures Tick Higher Ahead of Key U.S. Retail Sales Data and More Big Bank Earnings

September S&P 500 E-Mini futures (ESU24) are trending up +0.12% this morning as market participants looked ahead to key U.S. retail sales data and quarterly reports from more big banks.

ESU24 : 5,699.99s (-0.31%)
DJT : 29.23 (-3.82%)
AAPL : 244.47 (-0.05%)
GS : 672.19 (+1.76%)
M : 15.31 (+1.80%)
UNH : 500.73 (-4.35%)
BAC : 46.53 (-0.92%)
MS : 140.71 (+1.27%)
PNC : 196.52 (+1.35%)
JBHT : 174.26 (+2.52%)
BOSS.D.DX : 46.010 (-1.01%)
RIO.LN : 5,081.000 (-0.08%)
Nasdaq Beats Q1 Revenue Estimates with Strong FinTech and Index Performance

Nasdaq (NDAQ) reported a strong first quarter, surpassing revenue expectations with significant contributions from its financial technology and index businesses. The company's financial technology unit...

QQQ : 539.37 (+0.23%)
NDAQ : 81.24 (+0.41%)
ALAB : 93.27 (+6.17%)
KYTX : 2.97 (-1.98%)
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?

The market's excited for these stocks, but there's no rush to buy them.

KYTX : 2.97 (-1.98%)
CGON : 27.37 (-4.03%)

Business Summary

Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.

See More

Key Turning Points

3rd Resistance Point 3.30
2nd Resistance Point 3.22
1st Resistance Point 3.10
Last Price 2.97
1st Support Level 2.89
2nd Support Level 2.81
3rd Support Level 2.68

See More

52-Week High 30.60
Fibonacci 61.8% 19.92
Fibonacci 50% 16.62
Fibonacci 38.2% 13.32
Last Price 2.97
52-Week Low 2.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion